Walleye Capital
ZBIO

Walleye Capital’s Zenas BioPharma ZBIO Stock Holding History

Walleye Capital’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Buy
209,050
+83,818
+67% +$1.67M 0.02% 787
2026
Q1 		$2.45M Buy
+125,232
New +$2.81M 0.01% 1307

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Walleye Capital's ZBIO Position: Q2 2026 in Review

Walleye Capital increased its Zenas BioPharma (ZBIO) stake by 67% in Q2 2026, buying an estimated $1.67M and bringing the position to 209,050 shares worth $5.31M. The position accounts for 0.02% of the portfolio, ranked #787.

Walleye Capital first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Walleye Capital held 209,050 shares of Zenas BioPharma worth $5.31M as of Q2 2026.
  • Walleye Capital bought 83,818 Zenas BioPharma shares in Q2 2026, an estimated $1.67M.
  • Zenas BioPharma made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #787 holding.
  • Walleye Capital first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.